Biosimilar medical products – licensing, pharmacovigilance and interchangeability

Publicado en línea: 15 jul 2016

Páginas: 27 - 36

DOI: https://doi.org/10.1515/prilozi-2016-0006

Palabras clave

Regulatory, biosimilars, biologics, licensing, interchangeability, pharmacovigilance, EMA

© 2016 Aleksandra Grozdanova et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.